Skip to main content

Table 1 Key model parameters

From: The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden

Parameter

Value

References

Baseline Fracture Risks

based on Fx type, age, and gender, BMD

[2, 13]

Fracture Relative Risks - GIOP

by fracture type based on age

[13]

Fracture after Fracture and Second Fracture Relative Risks

based on fracture type and age

[13, 14]

Drug Costs

Teriparatide- Avg. Daily Cost: €14.74

[15]

 

Alendronate – Avg. Daily Cost: €0.42

 

Acute and Long-Term Direct Fracture Costs

by age and fracture type

[14, 28]

Currency SEK to € Conversion

9.0335 ; 12 month average ending December 2011

[16]

Continuing 6 Month Care Costs

€201 (months 1–6,13-18)

[17]

 

€194 (months 7–12)

 

Natural Mortality

Swedish Life Tables based on age and gender; adjusted to remove osteoporosis fracture deaths

[13, 18]

Fracture Mortality

based on age and gender;

[13]

 

0.007 (65 year male) to 0.0375 (90+ year old female)

 

Relative Risk of Mortality Post Fracture

For hip fractures and vertebral fractures; ranges: 2.5 (year 1) to 1.0 (year 7)

[19, 20]

Base Health Utilities

by age; from 0.84 (through age 50) to 0.65 (age 85)

[21]

Fracture Utility Multipliers

first year and subsequent years, by fracture type

[13]

Teriparatide Anti-Fracture Efficacies Relative Risks

by fracture type and treatment period

[47]

Bisphosphonate Anti-Fracture Efficacies Relative Risks

by fracture type and treatment period

[13]

Teriparatide Discontinuation

3, 9, and 15 month values interpolated to 6 month cycles

[22]

Bisphosphonate Discontinuation

by 6 month cycle

[23]